Clinical trials recruiting in Mianyang, China

Phase breakdown

Conditions recruiting in Mianyang, China

Recruiting trials in Mianyang, China

• A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
  NCT07564596 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
  NCT07010263 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
  NCT07098338 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of SCTB35 in Patients with Systemic Lupus Erythematosus
  NCT06841042 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study to Assess the Safety and PK/PD of LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus
  NCT07323173 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female)
• A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients
  NCT06155084 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male
• A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma
  NCT06471257 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
  NCT05899608 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
  NCT05485961 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
  NCT06300177 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
  NCT06959095 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• Efficacy and Influencing Factors of ALIC-NAc Deep Brain Stimulation in Treatment-Refractory Obsessive-Compulsive Disorder
  NCT07031544 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 65 Years · Sex: All (male and female)
• Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)
  NCT06569524 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
  NCT06307665 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female)
• FlashPoint Renal Denervation Under Columbus 3D Mapping System Guidance for Treating Hypertension
  NCT05590871 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 70 Years · Sex: All (male and female)
• Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
  NCT05334277 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• IMPACT COPD Cohort (China)
  NCT07382986 · Phase: Not specified · Ages: 40 Years to 80 Years · Sex: All (male and female)
• Left Atrial Appendage Closure as Secondary Prevention of Atrial Fibrillation-related Embolic Events
  NCT04559243 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
  NCT07363642 · Phase: Phase 3 · Ages: 12 Years to 80 Years · Sex: All (male and female)
• Phase II Study of RC1416 Injection in COPD
  NCT07402551 · Phase: Phase 2 · Ages: 40 Years to 85 Years · Sex: All (male and female)
• Phase II Trial of RC1416 Injection in Asthma
  NCT07403487 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUre
  NCT07687186 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
  NCT07222800 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• The Prevalence of COPD in Patients With Cardiovascular Disease and the Benefit of Cardiopulmonary Co-management
  NCT06909773 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years and older · Sex: All (male and female)
• This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab
  NCT06862206 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Mianyang, China?

25 recruiting trials have at least one study site in Mianyang, China.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.